Press Release

  • Press Release
  • No Likes

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency
The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency 150 150 Press Release
ABVC a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the visionary new CEO of ABVC has selflessly chosen to forgo a salary, instead opting for stock options as a pivotal component of his compensation package. read more
  • Press Release
  • No Likes

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam)as the new Chief Executive Officer (CEO). read more
  • Press Release
  • No Likes

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production 150 150 Press Release
BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. This agreement marks the second year of a partnership that grants Define Biotech the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan. read more
  • Russ Jaimes
  • No Likes

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF 150 150 Russ Jaimes
ABVC based in Fremont, California, signed a collaborative agreement with MerDury BioPharma on June 1st, 2023 to co-develop new drug products leveraging MerDury’s StackDoseTM platform technology. read more
  • Press Release
  • No Likes

Summer 2023: Investor Presentation
Summer 2023: Investor Presentation 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC) has announced the launch of its new pitch deck, presenting transformative advancements in biopharmaceuticals to potential investors. read more
  • Press Release
  • No Likes

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization
ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization 150 150 Press Release
ABVC based in Fremont, California, signed a collaborative agreement with MerDury BioPharma on June 1st, 2023 to co-develop new drug products leveraging MerDury’s StackDoseTM platform technology. read more
  • Press Release
  • No Likes

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC today announced that the Vitrargus® Phase II study at the Sydney Eye Hospital in New South Wales, Australia received ethical approval from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) on May 15, 2023. read more
  • Press Release
  • No Likes

ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder 150 150 Press Release
ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it received a US patent certificate for the treatment of Major Depressive Disorder (MDD) on April 25, 2023. read more
  • Press Release
  • No Likes

ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the site initiation visits (SIV) at the University of California San Francisco (UCSF) Medical Center was conducted on March 29, 2023. read more
  • Press Release
  • No Likes

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC) 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Phase 1 Site Initiation Visit (SIV) of ABV-1601 was successfully conducted at Cedars-Sinai Medical Center (CSMC) in West Hollywood… read more

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.